Deciphera Pharmaceuticals Inc (DCPH) is looking forward to a strong quarter

With 0.91 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.54 million shares. The 52-week range on DCPH shows that it touched its highest point at $17.73 and its lowest point at $9.90 during that stretch. It currently has a 1-year price target of $23.45. Beta for the stock currently stands at 0.38.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DCPH was up-trending over the past week, with a rise of 3.48%, but this was down by -5.57% over a month. Three-month performance dropped to -4.08% while six-month performance rose 23.70%. The stock gained 2.01% in the past year, while it has lost -2.29% so far this year. A look at the trailing 12-month EPS for DCPH yields -2.29 with Next year EPS estimates of -1.70. For the next quarter, that number is -0.55. This implies an EPS growth rate of 5.58% for this year and 21.20% for next year. EPS is expected to grow by 21.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 4.07%.

Float and Shares Shorts:

At present, 80.50 million DCPH shares are outstanding with a float of 49.41 million shares on hand for trading. On Mar 15, 2024, short shares totaled 5.65 million, which was 6.99% higher than short shares on Feb 15, 2024. In addition to DCTH as the firm’s Delcath Systems, Inc., DCPH serves as its Deciphera Pharmaceuticals, Inc.

Institutional Ownership:

Through their ownership of 73.38% of DCPH’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DCPH since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, DCPH has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and DCPH currently yields $0.00. In the past year, DCPH’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, DCPH has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.